Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isadora Rosa

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
World Journal of Surgical Oncology|November 29, 2024
Neoadjuvant therapy in rectal cancer-one year follow-up results of standard versus total neoadjuvant strategiesLuís Correia Gomes, Bernardo Alves Pereira, Isália Miguel, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 18, 2023
Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximabPaula Sousa, Marta Patita, Bruno Arroja, et al.
Scandinavian Journal of Gastroenterology|May 28, 2020
Methylation patterns in dysplasia in inflammatory bowel disease patientsIsadora Rosa, Patrícia Silva, Sara da Mata, et al.
Journal of Crohn'S & Colitis|March 15, 2025
T-cell branched glycosylation as a mediator of colitis-associated colorectal cancer progression: a potential new risk biomarker in inflammatory bowel diseaseEduarda Leite-Gomes, Mariana C Silva, Ana M Dias, et al.
Genes, Chromosomes & Cancer|April 11, 2019
The nonsense mutation MSH2 c.2152C>T shows a founder effect in Portuguese Lynch syndrome familiesManuela Pinheiro, Inês Francisco, Carla Pinto, et al.
Therapeutic Advances in Gastroenterology|September 22, 2017
Clinical performance of an infliximab rapid quantification assayFernando Magro, Joana Afonso, Susana Lopes, et al.
Journal of Crohn'S & Colitis|January 20, 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease PatientsFernando Magro, Samuel Fernandes, Marta Patita, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 13, 2021
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 YearsFernando Magro, Diogo Magalhães, Marta Patita, et al.
Journal of Crohn'S & Colitis|August 12, 2025
Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on InfliximabFernando Magro, Beatriz Domingues, Maria Manuela Estevinho, et al.
Ebiomedicine|June 21, 2017
Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic EscalationFernando Magro, Joana Afonso, Susana Lopes, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
World Journal of Surgical Oncology|November 29, 2024
Neoadjuvant therapy in rectal cancer-one year follow-up results of standard versus total neoadjuvant strategiesLuís Correia Gomes, Bernardo Alves Pereira, Isália Miguel, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 18, 2023
Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximabPaula Sousa, Marta Patita, Bruno Arroja, et al.
Scandinavian Journal of Gastroenterology|May 28, 2020
Methylation patterns in dysplasia in inflammatory bowel disease patientsIsadora Rosa, Patrícia Silva, Sara da Mata, et al.
Journal of Crohn'S & Colitis|March 15, 2025
T-cell branched glycosylation as a mediator of colitis-associated colorectal cancer progression: a potential new risk biomarker in inflammatory bowel diseaseEduarda Leite-Gomes, Mariana C Silva, Ana M Dias, et al.
Genes, Chromosomes & Cancer|April 11, 2019
The nonsense mutation MSH2 c.2152C>T shows a founder effect in Portuguese Lynch syndrome familiesManuela Pinheiro, Inês Francisco, Carla Pinto, et al.
Therapeutic Advances in Gastroenterology|September 22, 2017
Clinical performance of an infliximab rapid quantification assayFernando Magro, Joana Afonso, Susana Lopes, et al.
Journal of Crohn'S & Colitis|January 20, 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease PatientsFernando Magro, Samuel Fernandes, Marta Patita, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 13, 2021
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 YearsFernando Magro, Diogo Magalhães, Marta Patita, et al.
Journal of Crohn'S & Colitis|August 12, 2025
Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on InfliximabFernando Magro, Beatriz Domingues, Maria Manuela Estevinho, et al.
Ebiomedicine|June 21, 2017
Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic EscalationFernando Magro, Joana Afonso, Susana Lopes, et al.
Pageof 6